Cerebral Glucose Metabolism Assessment in Rat Models of Alzheimer's Disease: An 18F-FDG-PET Study

American Journal of Alzheimer's Disease and other Dementias

Volumn 31, Issue 4, 2016, Pages 333-340

  Lu, Yangjia ^a,b   Ren, Jie ^a   Cui, Shaoyang ^c,d   Chen, Junqi ^a,e   Huang, Yong ^a   Tang, Chunzhi ^b,c   Shan, Baoci ^f   Nie, Bingbing ^f   Xinsheng, Lai ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^d Futian Hospital   (China)

^e THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^f INSTITUTE OF HIGH ENERGY PHYSICS   (China)

Author keywords

Alzheimer's disease; metabolism; PET; rat model

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALACTOSE; GLUCOSE; IBOTENIC ACID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CEREBELLUM; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; EARLY DIAGNOSIS; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; HYPOTHALAMUS; IMAGE PROCESSING; INSULA; MALE; MEMORY; MESENCEPHALON; NONHUMAN; OLFACTORY BULB; PARIETAL LOBE; PONS ANGLE; POSITRON EMISSION TOMOGRAPHY; PYRIFORM CORTEX; RAT; RETROSPLENIAL CORTEX; SPATIAL LEARNING; STRIA TERMINALIS; THALAMUS; Y-MAZE TEST; ANIMAL; BRAIN CORTEX; DISEASE MODEL; METABOLISM; PROCEDURES; WISTAR RAT;

ALZHEIMER DISEASE; ANIMALS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; MALE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, WISTAR;

EID: 84968739674     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317515617725     Document Type: Article

References (64)

1. Cummings JL, Isaacson RS, Schmitt FA, Velting DM,. A practical algorithm for managing Alzheimer's disease: what, when, and why? Ann Clin Transl Neurol. 2015; 2 (3): 307-323.
2. Wisniewski T, Goñi F,. Immunotherapeutic approaches for Alzheimer's disease. Neuron. 2015; 85 (6): 1162-1176.
3. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer's disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71: 362-381.
4. Wurtman R,. Biomarkers in the diagnosis and management of Alzheimer's disease. Metabolism. 2015; 64 (3): 47-50.
5. Sperling RA, Karlawish J, Johnson KA,. Preclinical Alzheimer disease -The challenges ahead. Nat Rev Neurol. 2013; 9 (1): 54-8.
6. Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain. 2013; 136 (pt 3): 844-58.
7. Haass C, Selkoe DJ,. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007; 8 (2): 101-112.
8. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG-PET. Neuroimage. 2002; 17: 302-316.
9. 18F-FDG-PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008; 49 (3): 390-398.
10. 18F-FDG PET. J Nucl Med. 2005; 46 (10): 1625-1632.
11. Ma Y, Zhang S, Li J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. Medicine. 2014; 93 (27): e150.
12. Davison CM, O'Brien JT,. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry. 2014; 29 (6): 551-561.
13. 18F-PET in mild and asymptomatic stages. Behav Neurol. 2009; 21 (1): 101-115.
14. Health Quality Ontario. Functional brain imaging: an evidence-based analysis. Ont Health Technol Assess Ser. 2006; 6 (22): 1-79.
15. Verel I., Visser G., Van Dongen G,. The promise of immuno-PET in radioimmunotherapy. J Nucl Med. 2005; 46: 164S-171S.
16. Boellaard R,. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009; 50: 11S-20S.
17. Lonsdale MN, Beyer T., Dual-modality PET/CT instrumentation: today and tomorrow. Eur J Radiol. 2010; 73: 452-460.
18. 14C-deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977; 28 (5): 897-916.
19. Haass C, Selkoe DJ,. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007; 8: 101-112.
20. Drzezga A, Becker JA, Van Dijk KR, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011; 134: 1635-1646.
21. Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, Chavoix C,. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by pet. implications for Alzheimer's disease. Brain. 1999; 122: 1519-1531.
22. Kandel ER, The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001; 294 (5544): 1030-1038.
23. Paxinos G, Watson C,. The RAT BRAIN IN STEREOTAXIC Coordinates. New York: Academic Press; 1998.
24. Braak H, Braak E,. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-259.
25. Mufson EJ, He B, Nadeem M,. Hippocampal proNGF signaling pathways and [beta]-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol. 2012; 71: 1018-1029.
26. Jiang J, Gao K, Zhou Y, et al. Electroacupuncture treatment improves learning-memory ability and brain glucose metabolism in a mouse model of Alzheimer's disease: using Morris water maze and micro-PET. Evid Based Complement Alternat Med. 2015; 2015: 142129.
27. Brickman AM, Honig LS, Scarmeas N, et al. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. 2008; 65 (9): 1202-1208.
28. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012; 69 (12): 1621-1627.
29. Brickman AM, Zahodne LB, Guzman VA, et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging. 2015; 36 (1): 27-32.
30. Bruner E, Jacobs HI,. Alzheimer's disease: the downside of a highly evolved parietal lobe? J Alzheimers Dis. 2013; 35 (2): 227-240.
31. Micotti E, Paladini A, Balducci C, et al. Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. Neurobiol Aging. 2015; 36 (2): 776-788.
32. Selkoe DJ,. Alzheimer's disease is a synaptic failure. Science. 2002; 298 (5594): 789-791.
33. Gil R, Arroyo-Anllo EM, Ingrand P, et al. Self-consciousness and Alzheimer's disease. Acta Neurol Scand. 2001; 104 (5): 296-300.
34. Arroyo-Anlló EM, Díaz JP, Gil R,. Familiar music as an enhancer of self-consciousness in patients with Alzheimer's disease. Biomed Res Int. 2013; 2013: 752965.
35. Wu N, Rao X, Gao Y, Wang J, Xu F,. Amyloid-β deposition and olfactory dysfunction in an Alzheimer's disease model. J Alzheimers Dis. 2013; 37 (4): 699-712.
36. Masurkar AV, Devanand DP,. Olfactory dysfunction in the elderly: basic circuitry and alterations with normal aging and Alzheimer's disease. Curr Geriatr Rep. 2014; 3 (2): 91-100.
37. Yuan TF, Slotnick BM,. Roles of olfactory system dysfunction in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 54: 26-30.
38. Wesson DW, Levy E, Nixon RA, Wilson DA,. Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. J Neurosci. 2010; 30 (2): 505-14.
39. Wesson DW, Borkowski AH, Landreth GE, Nixon RA, Levy E, Wilson DA,. Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model. J Neurosci. 2011; 31 (44): 15962-15971.
40. Prestia A, Drago V, Rasser PE, Bonetti M, Thompson PM, Frisoni GB,. Cortical changes in incipient Alzheimer's disease. J Alzheimers Dis. 2010; 22 (4): 1339-1349.
41. Fischer CE, Ting WK, Millikin CP, et al. Gray matter atrophy in patients with mild cognitive impairment/Alzheimer's disease over the course of developing delusions. Int J Geriatr Psychiatry. 2015.
42. Nakaaki S, Sato J, Torii K, et al. Decreased white matter integrity before the onset of delusions in patients with Alzheimer's disease: diffusion tensor imaging. Neuropsychiatr Dis Treat. 2013; 9: 25-29.
43. Sokoloff L,. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem. 1977; 29: 13-26.
44. Liu X, Erikson C, Brun A,. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. Dementia. 1996; 7: 128-134.
45. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7 (3): 263-269.
46. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7 (3): 280-292.
47. Xia M, Wang Z, Dai Z, et al. Differentially disrupted functional connectivity in posteromedial cortical subregions in Alzheimer's disease. J Alzheimers Dis. 2014; 39 (3): 527-543.
48. Woost TB, Dukart J, Frisch S, et al. Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration-a combined MRI & FDG-PET study. Neuroimage Clin. 2013; 2: 746-58.
49. Sorg C, Myers N, Redel P, et al. Asymmetric loss of parietal activity causes spatial bias in prodromal and mild Alzheimer's disease. Biol Psychiatry. 2012; 71 (9): 798-804.
50. Teune LK, Strijkert F, Renken RJ, et al. The Alzheimer's disease-related glucose metabolic brain pattern. Curr Alzheimer Res. 2014; 11 (8): 725-732.
51. Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC,. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003; 60 (8): 1374-1377.
52. Mosconi L,. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005; 32 (4): 486-510.
53. Sato N, Morishita R,. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci. 2013; 5: 64.
54. van Exel E, Eikelenboom P, Comijs H, et al. Insulin-like growth factor-1 and risk of late-onset Alzheimer's disease: findings from a family study. Neurobiol Aging. 2014; 35 (3): 725.
55. Rudolf J, Ghaemi M, Ghaemi M, et al. Alterations of cerebral glucose metabolism and benzodiazepine receptor binding in acute and persistent vegetative state. J Cereb Blood Flow Metabol. 1999; 19: S839.
56. Cao Q, Jiang K, Liu Y, et al. The comparison of the regional cerebral metabolism rate of glucose in Alzheimer's disease with mild cognitive impairment. Zhonghua Yi Xue Za Zhi. 2002; 82 (23): 1613-1616.
57. Sorg C, Myers N, Redel P, et al. Asymmetric loss of parietal activity causes spatial bias in prodromal and mild Alzheimer's disease. Biol Psychiatry. 2012; 71 (9): 798-804.
58. Li H, Guo Q, Inoue T, et al. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener. 2014; 9: 28.
59. Sakamoto S, Ishii K,. Low cerebral glucose extraction rates in the human medial temporal cortex and cerebellum. J Neurol Sci. 2000; 172: 41-48.
60. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 280-292.
61. Cerami C, Della Rosa PA, Magnani G, et al. Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia. Neuroimage Clin. 2014; 7: 187-94.
62. Hu J, Wang Q, Liang W,. Effects of bushen yizhi recipe on somatostatin-like immunopositive and somatostatin messenger ribonucleic acid expressed-positive neurons in Alzheimer's disease model rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000; 20 (7): 533-535.
63. Zhong ZG, Qu ZQ, Wang NP, et al. Effects of the Panax notoginseng saponins on the level of synaptophysin protein in brain in rat model with lesion of Meynert. Zhongguo Zhong Yao Za Zhi. 2005; 30 (12): 913-915.
64. Zhong Z, Qu Z, Wang N, et al. Protective effects of Panax notoginseng saponins against pathological lesion of cholinergic neuron in rat model with Alzheimer' s disease. Zhong Yao Cai 2005; 28 (2): 119-122.